Caplin Point Laboratories has notified the stock exchanges of an upcoming board meeting scheduled for Thursday, May 14, 2026, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will take up key agenda items pertaining to the company's financial performance and shareholder returns for the fiscal year ended March 31, 2026.

Board Meeting Agenda

The board of directors will convene to consider and approve the following matters, as outlined in the company's intimation dated May 07, 2026:

Trading Window Closure

In line with the company's Code of Conduct to regulate, monitor, and report trading by insiders, and in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's scrips by Designated Persons commenced on April 1, 2026 and will remain closed until May 16, 2026 (both days inclusive). This closure was communicated to the exchanges earlier vide the company's letter dated March 27, 2026.

Regulatory Filing

The board meeting intimation was signed by Venkatram G, General Counsel & Company Secretary (Membership No. A23989), on behalf of Caplin Point Laboratories, and submitted to both BSE Limited and the National Stock Exchange of India Ltd. on May 07, 2026. The filing underscores the company's adherence to its disclosure obligations under applicable SEBI regulations.

Caplin Steriles Limited (CSL), a subsidiary of Caplin Point Laboratories , announced on May 05, 2026, that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP. The approval covers the 100 mg/mL formulation available in 10 mL, 50 mL, and 100 mL vials, representing a generic therapeutic equivalent of the Reference Listed Drug (RLD) from Fresenius Kabi USA, LLC (NDA 208418).

Approval Details

The following table summarises the key parameters of the USFDA approval received by Caplin Steriles Limited:

Therapeutic Indication and Market Size

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. According to IQVIA™ (IMS Health), Calcium Gluconate Injection USP (100 mg/mL in 10 mL, 50 mL and 100 mL Vials) recorded US sales of approximately $71 million for the 12-month period ending March 2026.

About Caplin Steriles Limited

Caplin Steriles Limited is a fast-growing sterile product manufacturing company approved by several regulatory agencies, including US FDA, EU-GMP, ANVISA, and INVIMA. Key highlights of CSL's regulatory and pipeline profile include:

• 54 ANDAs filed in the USA on its own and with partners, with 54 approvals (including acquired ANDAs) so far
• A portfolio of 55+ simple and complex Injectable and Ophthalmic products intended to be filed over the next 4 years
• Multiple products filed with several approvals in non-US markets including Australia, Canada, Mexico, Chile, UAE, Hong Kong, Malaysia, South Africa, and Saudi Arabia

About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa, with state-of-the-art manufacturing facilities covering a complete range of finished dosage forms. The company has appeared on Forbes "Asia's 200 Best Under a Billion" list for 7 times in the last 10 years, and was awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

Caplin One Labs Limited (COL), another subsidiary of Caplin Point Laboratories Limited, is in the second year of its operations at its oncology unit in Kakkalur, with various ongoing projects in different stages of completion for generic and specialty products for both regulated and other markets. COL holds 5 approved ANDAs for Injectable products.